Cost-offset analysis: bimatoprost versus other prostaglandin analogues in open-angle glaucoma.

@article{Berenson2011CostoffsetAB,
  title={Cost-offset analysis: bimatoprost versus other prostaglandin analogues in open-angle glaucoma.},
  author={Karina L Berenson and Steven M Kymes and David A. Hollander and Richard G Fiscella and Caroline T. Burk and Vaishali D Patel},
  journal={The American journal of managed care},
  year={2011},
  volume={17 9},
  pages={e365-74}
}
OBJECTIVES To develop a cost-offset model from a US payer perspective comparing glaucomatous progression and costs among primary open-angle glaucoma (POAG) patients using bimatoprost, latanoprost, or travoprost. STUDY DESIGN Cost-offset model. METHODS A Markov cohort model was used to estimate glaucomatous progression for POAG patients over 7 years. The model assumed bimatoprost-treated patients had lower resulting intraocular pressure (IOP) (by 1 mm Hg) for all presenting IOP categories… CONTINUE READING